Abstract： Objective To detect the expression of miR-106a in endometrial carcinoma, atypical hyperplasia and normal endometrium tissues. And to investigate the relationship between the expression of miR-106a and the origination, development, invasion and metastasis of endometrial carcinoma. Methods The endometrium tissue samples from forty patients with endometrial carcinoma, twenty patients with atypical hyperplasia and thirty patients with normal endometrium (from female with abnormal uterine bleeding and myoma uteri) were collected, poly (A)-RT-qPCR was employed to test the expression of miR-106a in different endometrial tissues. The statistical analyses were performed between the expression of miR-106a, miR-10a and the clinicopathological characteristics of endometrial carcinoma. Results The relative expression of miR-106a in endometrial carcinoma, atypical hyperplasia and normal endometrium tissues were 0.667 (0.197, 1.624), 0.245 (0.064, 0.759) and 0.104 (0.003, 1.350) respectively, the expression gradually declined, and the difference was statistically significant (P<0.01). The expression of miR106a in endometrial carcinoma tissues was higher than that in normal endometrium tissues (P<0.01), and atypical hyperplasia tissues (P<0.05), but the difference between normal endometrium and atypical hyperplasia tissues was no statistical significance (P>0.05); The expression of miR-106a in stage III+IV of endometrial carcinoma patients was higher than stage I+II, in patients with lymph node metastasis were higher than that without lymph node metastasis, the difference was statistically significant (P<0.01); The expression of miR-106a in different ages pathological types, pathological grades, myometrial invasion and whether ER-positive, PR-positive of endometrial carcinoma patients had no statistical difference (P>0.05). Conclusions The expression of miR-106a was up-regulated in endometrial carcinoma tissues, it may regulate the origination and development of endometrial carcinoma as an oncogene.
